Cargando…
Metabolomic analysis of uterine serous carcinoma with acquired resistance to paclitaxel
INTRODUCTION: Uterine serous carcinoma (USC) is more aggressive than other subtypes of endometrial carcinoma and is associated with a poor prognosis. We analyzed the metabolomic profile of USC with acquired resistance to paclitaxel. RESULTS: Glutathione (GSH) concentration in PTX-1 cells was higher...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6112827/ https://www.ncbi.nlm.nih.gov/pubmed/30174791 http://dx.doi.org/10.18632/oncotarget.25868 |
_version_ | 1783350911124373504 |
---|---|
author | Seino, Manabu Ohta, Tsuyoshi Sugiyama, Akiko Sakaki, Hirotsugu Sudo, Takeshi Tsutsumi, Seiji Shigeta, Shogo Tokunaga, Hideki Toyoshima, Masafumi Yaegashi, Nobuo Nagase, Satoru |
author_facet | Seino, Manabu Ohta, Tsuyoshi Sugiyama, Akiko Sakaki, Hirotsugu Sudo, Takeshi Tsutsumi, Seiji Shigeta, Shogo Tokunaga, Hideki Toyoshima, Masafumi Yaegashi, Nobuo Nagase, Satoru |
author_sort | Seino, Manabu |
collection | PubMed |
description | INTRODUCTION: Uterine serous carcinoma (USC) is more aggressive than other subtypes of endometrial carcinoma and is associated with a poor prognosis. We analyzed the metabolomic profile of USC with acquired resistance to paclitaxel. RESULTS: Glutathione (GSH) concentration in PTX-1 cells was higher than in USPC-1 cells. In addition, GSH concentration in the USPC-1 cells increased after treatment with paclitaxel but was unchanged in PTX-1 cells. Glucose-6-phosphate (G6P) and ribose-5-phosphate (R5P) concentrations in PTX-1 cells were higher than those in USPC-1 cells. G6P concentration in the USPC-1 cells was unchanged after treatment with paclitaxel, while it decreased in PTX-1 cells. CONCLUSION: Our results indicate that increased GSH and glucose metabolism may be related to acquiring resistance to paclitaxel in USC and thus may be targets for anti-USC therapy. MATERIALS AND METHODS: We compared metabolic profiles and reactions to paclitaxel in both a wild type USC cell line (USPC-1) and PTX-1, a cell line derived from USPC-1 which acquired paclitaxel resistance, using a capillary electrophoresis CE-MS/MS system. |
format | Online Article Text |
id | pubmed-6112827 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-61128272018-08-31 Metabolomic analysis of uterine serous carcinoma with acquired resistance to paclitaxel Seino, Manabu Ohta, Tsuyoshi Sugiyama, Akiko Sakaki, Hirotsugu Sudo, Takeshi Tsutsumi, Seiji Shigeta, Shogo Tokunaga, Hideki Toyoshima, Masafumi Yaegashi, Nobuo Nagase, Satoru Oncotarget Research Paper INTRODUCTION: Uterine serous carcinoma (USC) is more aggressive than other subtypes of endometrial carcinoma and is associated with a poor prognosis. We analyzed the metabolomic profile of USC with acquired resistance to paclitaxel. RESULTS: Glutathione (GSH) concentration in PTX-1 cells was higher than in USPC-1 cells. In addition, GSH concentration in the USPC-1 cells increased after treatment with paclitaxel but was unchanged in PTX-1 cells. Glucose-6-phosphate (G6P) and ribose-5-phosphate (R5P) concentrations in PTX-1 cells were higher than those in USPC-1 cells. G6P concentration in the USPC-1 cells was unchanged after treatment with paclitaxel, while it decreased in PTX-1 cells. CONCLUSION: Our results indicate that increased GSH and glucose metabolism may be related to acquiring resistance to paclitaxel in USC and thus may be targets for anti-USC therapy. MATERIALS AND METHODS: We compared metabolic profiles and reactions to paclitaxel in both a wild type USC cell line (USPC-1) and PTX-1, a cell line derived from USPC-1 which acquired paclitaxel resistance, using a capillary electrophoresis CE-MS/MS system. Impact Journals LLC 2018-08-10 /pmc/articles/PMC6112827/ /pubmed/30174791 http://dx.doi.org/10.18632/oncotarget.25868 Text en Copyright: © 2018 Seino et al. https://creativecommons.org/licenses/by/3.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (https://creativecommons.org/licenses/by/3.0/) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Paper Seino, Manabu Ohta, Tsuyoshi Sugiyama, Akiko Sakaki, Hirotsugu Sudo, Takeshi Tsutsumi, Seiji Shigeta, Shogo Tokunaga, Hideki Toyoshima, Masafumi Yaegashi, Nobuo Nagase, Satoru Metabolomic analysis of uterine serous carcinoma with acquired resistance to paclitaxel |
title | Metabolomic analysis of uterine serous carcinoma with acquired resistance to paclitaxel |
title_full | Metabolomic analysis of uterine serous carcinoma with acquired resistance to paclitaxel |
title_fullStr | Metabolomic analysis of uterine serous carcinoma with acquired resistance to paclitaxel |
title_full_unstemmed | Metabolomic analysis of uterine serous carcinoma with acquired resistance to paclitaxel |
title_short | Metabolomic analysis of uterine serous carcinoma with acquired resistance to paclitaxel |
title_sort | metabolomic analysis of uterine serous carcinoma with acquired resistance to paclitaxel |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6112827/ https://www.ncbi.nlm.nih.gov/pubmed/30174791 http://dx.doi.org/10.18632/oncotarget.25868 |
work_keys_str_mv | AT seinomanabu metabolomicanalysisofuterineserouscarcinomawithacquiredresistancetopaclitaxel AT ohtatsuyoshi metabolomicanalysisofuterineserouscarcinomawithacquiredresistancetopaclitaxel AT sugiyamaakiko metabolomicanalysisofuterineserouscarcinomawithacquiredresistancetopaclitaxel AT sakakihirotsugu metabolomicanalysisofuterineserouscarcinomawithacquiredresistancetopaclitaxel AT sudotakeshi metabolomicanalysisofuterineserouscarcinomawithacquiredresistancetopaclitaxel AT tsutsumiseiji metabolomicanalysisofuterineserouscarcinomawithacquiredresistancetopaclitaxel AT shigetashogo metabolomicanalysisofuterineserouscarcinomawithacquiredresistancetopaclitaxel AT tokunagahideki metabolomicanalysisofuterineserouscarcinomawithacquiredresistancetopaclitaxel AT toyoshimamasafumi metabolomicanalysisofuterineserouscarcinomawithacquiredresistancetopaclitaxel AT yaegashinobuo metabolomicanalysisofuterineserouscarcinomawithacquiredresistancetopaclitaxel AT nagasesatoru metabolomicanalysisofuterineserouscarcinomawithacquiredresistancetopaclitaxel |